InvestorsHub Logo
Followers 103
Posts 16378
Boards Moderated 0
Alias Born 07/29/2011

Re: mckinley1 post# 36739

Friday, 02/12/2016 3:37:02 PM

Friday, February 12, 2016 3:37:02 PM

Post# of 77155
FYI.....
Mr. Karras stated, “Timing is everything, and I see this opportunity with Easton Pharmaceuticals as an extremely high-growth undertaking. What especially excites me is that Easton is in a ground-floor position to leverage its partnerships in the Women’s Health arena and make a major impact in the market with the launch of a suite of patented, in-licensed products in Latin America, a unique position when one considers these same licenses were negotiated for in other territories by some of the largest pharma companies in the world.” Mr. Karras further commented, “Latin America is a very high-growth region for the pharmaceutical industry and I can see additional opportunities for Easton revenues in generic cancer drug sales, as well as with the development of its proprietary cancer compounds. We intend to not only grow in Latin America but across the world in other markets such as the Middle East, and even North America, with some of the other unique product offerings Easton has within the Women’s Health industry.”